Elaphron is pioneering a new therapeutic approach through a novel class of oral, non-systemic therapies designed to address persistent limitations in current standards of care.
RETHINKING OBESITY:
INVESTIGATING METABOLIC HEALTH FIRST APPROACH
Designed to improve metabolic health and drive weight loss while preserving adequate nutrition, lean mass, physical performance, quality of life, and enjoyment of food.
Elaphron is developing a new approach to obesity treatment built around a different therapeutic sequence:
Improve Metabolic Health First → Weight Loss Follows
CURRENT APPETITE-SUPPRESSIVE THERAPIES
Reduced Food Intake → Energy Deficit → Weight Loss With → Improved Metabolic Health
Appetite-suppressive therapies have transformed obesity care. Their primary therapeutic pathway relies on reducing food intake to create an energy deficit that drives weight loss, with important metabolic benefits occurring alongside and following weight reduction.
METABOLIC SURGERY REVEALS ANOTHER PATH
Altered Gut Signaling → Rapid Metabolic Improvement → Weight Loss
Improvements in metabolic health following bariatric surgery are profound and can emerge rapidly, before substantial weight loss, and the magnitude of these changes can exceed what would be expected from caloric restriction or weight loss alone.
Subsequent weight loss can also exceed what would be expected from surgically induced caloric restriction alone. Together, these observations support an important role for altered nutrient flow and food- and nutrient-driven gut signaling in driving both metabolic improvement and weight loss.
EL-924: DESIGNED AROUND THAT BIOLOGY
EL-924 is designed to recreate selected metabolic effects of bariatric surgery without surgery by modulating food- and nutrient-driven gut signaling.
Metabolic Health First → Weight Loss Follows
By improving metabolic health without relying primarily on appetite suppression, EL-924 is designed to support adequate nutrition, lean mass preservation, physical performance, GI tolerability, and quality of life throughout the weight-loss journey.
The goal: sustainable weight loss while preserving quality of life.
HOW OUR PLATFORM WORKS
Following oral administration, Elaphron therapies form a locally acting, minimally absorbed protective hydrogel that transiently interfaces with the gastrointestinal epithelium.
Together with associated bioactive complexes, this interface is designed to modulate interactions among nutrients, bile acids, the intestinal surface, and local signaling pathways—reshaping food- and nutrient-driven gut signaling in a directionally similar manner to selected metabolic effects of bariatric surgery, while acting locally within the GI tract without systemic absorption.
BEYOND OBESITY
Metabolic dysfunction is not limited to obesity. Approximately 20–30% of normal-weight adults may be metabolically unhealthy, with insulin resistance, metabolic dyslipidemia, and abnormal visceral or ectopic fat despite normal BMI—creating substantial long-term cardiometabolic risk.
A therapy designed to improve metabolic health independently of appetite suppression and substantial weight loss could therefore have applications beyond obesity itself.
The same Elaphron platform can also be engineered to protect the intestinal epithelium and modulate local pathways involved in mucosal injury, inflammation, hypersecretion, and gastrointestinal dysfunction—creating opportunities for locally acting therapies across a broader range of GI-driven diseases.
More than one billion people worldwide are living with obesity, a complex chronic disease and one of the largest unmet needs in global health.
Incretin-based therapies have transformed obesity treatment, demonstrating that substantial weight loss and meaningful cardiometabolic benefits are achievable.
However, translating this efficacy into durable population-level benefit remains challenging. Long-term persistence, treatment discontinuation and weight regain, tolerability, variable response, lean-mass preservation, cost and access, and the need for chronic therapy continue to leave important gaps.
The next generation of obesity therapies can build on this progress with complementary mechanisms that broaden treatment options beyond appetite suppression and weight loss alone—addressing the underlying biology of obesity and its associated metabolic dysfunction. The next frontier is sustainability.
To establish a new therapeutic category for obesity and metabolic disease: oral, non-systemic therapies that act through the gastrointestinal tract without relying primarily on appetite suppression or chronic systemic exposure.
To translate the profound metabolic biology revealed by bariatric surgery into simple, oral, well-tolerated therapies that can be used at population scale.
The intestine is a key regulator of metabolic homeostasis. For decades, the only way to harness its profound metabolic effects was through bariatric/metabolic surgery.
The metabolic effects of bariatric surgery extend far beyond surgically induced dieting or portion control. Metabolic surgery changes how nutrients interact with the gastrointestinal tract, rapidly reshaping nutrient sensing, gut-derived hormonal and metabolic signaling, and whole-body metabolic regulation. Many of these effects emerge before substantial weight loss, demonstrating that the intestine itself is a powerful regulator of metabolic homeostasis.
Elaphron is developing oral, non-systemic locally acting therapies designed to target this biology without surgery. By modulating how luminal nutrients engage receptors, transporters, and signaling pathways in the proximal intestine, Elaphron aims to influence meal-driven gut–organ communication and reproduce selected metabolic effects associated with bariatric surgery—without an invasive procedure or chronic systemic drug exposure.
Local activity, minimal systemic exposure
Designed to improve metabolic regulation without relying on appetite suppression
Designed for use alone or alongside existing metabolic therapies
Our core team working together has repeatedly translated scientific invention into later clinical-stage therapies—conceiving new therapeutic approaches, developing enabling technologies, and advancing two first-in-class therapies from concept through Phase II, with one now progressing toward Phase III.
This track record has earned international recognition and support, including engagement with the WHO GTFCC and support from the European Union. It also led to a multinational consortium spanning 10 countries across three continents to advance a therapy based on our technology toward Phase III.
At Elaphron, we are applying this combination of scientific invention, technology development, and translational execution to advance a new generation of therapies for metabolic and gastrointestinal disease.
A Potentially De-Risked Development Path
Early FDA engagement has helped define a potentially streamlined path toward clinical development.
Following an FDA INTERACT meeting, Elaphron received feedback supporting the potential use of a 505(b)(2) development pathway for substantial portions of the program, leveraging existing human safety information for EL-924’s constituent components.
FDA feedback also provided a framework for a potentially reduced IND-enabling program, including the potential use of a single-species repeat-dose toxicology program and a more focused PK/ADME package, subject to appropriate supporting data and further FDA review.
Together, this feedback has the potential to reduce the time, cost, and execution risk required to reach early clinical proof of concept.
A rapidly emerging therapeutic field, supported by the profound metabolic outcomes observed following bariatric surgery and growing validation across multiple programs.
Inflammatory Bowel Disease IBD
Irritable Bowel Syndrome (IBS)&SIBO
